In this prospective observation report, we focused on the effect of the PI3K inhibitor alpelisib, which was recently approved by the FDA and EMA for the treatment of PIK3CA-mutated, hormone receptor-negative advanced breast cancer, showing very promising results8. Here, PIK3CA is linked to breast carcinoma.